<< Researchers predict diabetes cases to double and cost to triple in the next 25 years | Free HIV testing service for Liverpool residents on World AIDS Day 2009 >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | हिन्दी | Русский | Svenska | Polski

Report on global osteoporosis therapeutics market

Published on November 27, 2009 at 1:18 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/2070d2/osteoporosis_thera) has announced the addition of the "Osteoporosis Therapeutics - A Global Market Perspective" report to their offering.

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.

These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen, Inc. This report is designed to be the most comprehensive in geographic coverage and vertical market analyses.

http://www.researchandmarkets.com/research/2070d2/osteoporosis_thera

Posted in: Pharmaceutical News

Tags: , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading